Mexico - North America Blood Cancer Diagnostics Market Size & Outlook
The blood cancer diagnostics market in Mexico - North America is expected to reach a projected revenue of US$ 253.6 million by 2030. A compound annual growth rate of 4.9% is expected of Mexico - North America blood cancer diagnostics market from 2025 to 2030.
The Mexico blood cancer diagnostics market generated a revenue of USD 190.1 million in 2024 and is expected to reach USD 253.6 million by 2030.
The Mexico market is expected to grow at a CAGR of 4.9% from 2025 to 2030.
In terms of segment, assay kits and reagents was the largest revenue generating product in 2024.
Assay Kits and Reagents is the most lucrative product segment registering the fastest growth during the forecast period.
Blood cancer diagnostics market data book summary
Market revenue in 2024
USD 190.1 million
Market revenue in 2030
USD 253.6 million
Growth rate
4.9% (CAGR from 2025 to 2030)
Largest segment
Assay kits and reagents
Fastest growing segment
Assay Kits and Reagents
Historical data
2018 - 2023
Base year
2024
Forecast period
2025 - 2030
Quantitative units
Revenue in USD million
Market segmentation
Instruments, Assay Kits and Reagents
Other key industry trends
In terms of revenue, Mexico accounted for 1.8% of the global blood cancer diagnostics market in 2024.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
In North America, U.S. blood cancer diagnostics market is projected to lead the regional market in terms of revenue in 2030.
Canada is the fastest growing regional market in North America and is projected to reach USD 769.6 million by 2030.
The advancement of molecular and genetic testing is driving the market growth. These technologies allow more precise diagnosis and classification of hematologic malignancies, which is crucial for tailoring treatment strategies.
In Mexico, the adoption of these advanced diagnostic tools has been growing across different regions and healthcare settings. Major urban centers tend to have better access to these technologies than more rural areas, highlighting disparities in healthcare provision.
In June 2024, Massive Bio, an oncology software company, partnered with Un Ensayo Para Mi (UEPM), a platform for clinical trial searches, to improve oncology clinical practices across Latin American countries such as Mexico, Brazil, Colombia, and Argentina. The partnership aims to leverage advanced AI technologies to improve the availability of clinical trials and enhance patient care. By utilizing Massive Bio's AI-driven solutions, the company aims to close the gap between cancer patients needing new treatments.
Mexico - North America Blood Cancer Diagnostics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Blood Cancer Diagnostics Market Outlook will help companies and investors design strategic landscapes.
Assay Kits And Reagents was the largest segment with a revenue share of 72.07% in 2024.
Horizon Databook has segmented the Mexico - North America blood cancer diagnostics market based on instruments, assay kits and reagents covering the revenue growth of each sub-segment from 2018 to 2030.
The advancement of molecular and genetic testing is driving the market growth. These technologies allow more precise diagnosis and classification of hematologic malignancies, which is crucial for tailoring treatment strategies.
In Mexico, the adoption of these advanced diagnostic tools has been growing across different regions and healthcare settings. Major urban centers tend to have better access to these technologies than more rural areas, highlighting disparities in healthcare provision.
In June 2024, Massive Bio, an oncology software company, partnered with Un Ensayo Para Mi (UEPM), a platform for clinical trial searches, to improve oncology clinical practices across Latin American countries such as Mexico, Brazil, Colombia, and Argentina. The partnership aims to leverage advanced AI technologies to improve the availability of clinical trials and enhance patient care. By utilizing Massive Bio's AI-driven solutions, the company aims to close the gap between cancer patients needing new treatments.
Mexico - North America Blood Cancer Diagnostics Market Product Outlook (Revenue, USD Million , 2018-2030)
Instruments
Assay Kits and Reagents
Mexico - North America Blood Cancer Diagnostics Market Test Outlook (Revenue, USD Million , 2018-2030)
Blood Tests
Imaging Tests
Biopsy
Molecular Test
Mexico - North America Blood Cancer Diagnostics Market Enduse Outlook (Revenue, USD Million , 2018-2030)
Hospitals and Clinics
Diagnostic Labs
Research Institutes
Reasons to subscribe to Blood Cancer Diagnostics Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Blood Cancer Diagnostics Market Outlook databook
Our clientele includes a mix of Blood Cancer Diagnostics Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico - North America Blood Cancer Diagnostics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Mexico - North America Blood Cancer Diagnostics Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Mexico - North America Blood Cancer Diagnostics Market, 2018-2030 (US$M)